سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية – اتجاهات الصناعة والتوقعات حتى عام 2031

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية – اتجاهات الصناعة والتوقعات حتى عام 2031

  • Pharmaceutical
  • Published Report
  • Oct 2024
  • North America
  • 350 الصفحات
  • عدد الجداول: 36
  • عدد الأرقام: 27

North America Hepatitis B Infection Market

حجم السوق بالمليار دولار أمريكي

CAGR :  % Diagram

Diagram فترة التنبؤ
2024 –2031
Diagram حجم السوق (السنة الأساسية)
USD 2.35 Billion
Diagram حجم السوق (سنة التنبؤ)
USD 3.45 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية، حسب النوع (مزمن وحاد)، حسب العلاج (اللقاح، الأدوية المضادة للفيروسات، أدوية تعديل المناعة ، والجراحة - اتجاهات الصناعة والتوقعات حتى عام 2031     

سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية

تحليل ورؤى حول سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية

تحلل شركة Data Bridge Market Research أن سوق عدوى التهاب الكبد B في أمريكا الشمالية من المتوقع أن يصل إلى 3.45 مليار دولار أمريكي بحلول عام 2031 من 2.35 مليار دولار أمريكي في عام 2023، بمعدل نمو سنوي مركب قدره 4.9٪ في الفترة المتوقعة من 2024 إلى 2031.

تقرير القياس

تفاصيل

فترة التنبؤ

2024 إلى 2031

سنة الأساس

2023

سنوات تاريخية

2022 (قابلة للتخصيص للفترة 2016-2021)

وحدات كمية

الإيرادات بالمليار دولار أمريكي

القطاعات المغطاة

 النوع (مزمن وحاد)، العلاج (اللقاح، الأدوية المضادة للفيروسات ، أدوية تعديل المناعة، والجراحة)  

الدول المغطاة

 الولايات المتحدة وكندا والمكسيك

الجهات الفاعلة في السوق المشمولة

 Gilead Sciences, Inc. (الولايات المتحدة)، GlaxoSmithKline plc (المملكة المتحدة)، Dynavax Technologies (الولايات المتحدة)، F. Hoffmann-La Roche Ltd (سويسرا)، Bristol-Myers Squibb Company (الولايات المتحدة)، Merck Sharp and Dohme Corp. (الولايات المتحدة)، Novartis AG (سويسرا)، Arrowhead Pharmaceuticals Inc. (الولايات المتحدة)، Arbutus Biopharma (كندا)، Teva Pharmaceuticals, Inc. (إسرائيل)، Zydus Pharmaceuticals (الهند)، Aurobindo Pharma (الهند)، Lupin Pharmaceuticals, Inc. (الهند)

تعريف السوق

يشير سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية إلى قطاع الرعاية الصحية الذي يركز على تشخيص وعلاج والوقاية من وإدارة عدوى فيروس التهاب الكبد الوبائي ب (HBV). يشمل هذا السوق مجموعة واسعة من المنتجات والخدمات، بما في ذلك اللقاحات والأدوية المضادة للفيروسات واختبارات التشخيص ومعدلات المناعة والعلاجات التي تهدف إلى معالجة كل من الأشكال الحادة والمزمنة من التهاب الكبد الوبائي ب. التهاب الكبد الوبائي ب هو مرض كبدي شديد العدوى يسببه فيروس التهاب الكبد الوبائي ب، والذي يمكن أن يؤدي إلى مضاعفات صحية خطيرة مثل تليف الكبد وفشل الكبد وسرطان الخلايا الكبدية. يشمل السوق شركات الأدوية وشركات التكنولوجيا الحيوية ومقدمي خدمات التشخيص ومرافق الرعاية الصحية ومؤسسات البحث التي تعمل على تطوير حلول علاجية متقدمة.

ديناميكيات سوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية

يتناول هذا القسم فهم محركات السوق والفرص والقيود والتحديات. وسيتم مناقشة كل هذا بالتفصيل أدناه:      

سائق

تزايد انتشار عدوى التهاب الكبد الوبائي ب

 The increasing prevalence of Hepatitis B infections serves as a significant driver in the North America Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies.

Restraint

  •  Side Effects and Drug Resistance
  • Side effects and drug resistance serve as significant restraints in the North America Hepatitis B infection market by limiting the effectiveness and long-term use of available therapies. Many antiviral drugs used to treat Hepatitis B can cause adverse effects such as fatigue, nausea, liver toxicity, and kidney damage, which can lead to poor patient adherence and treatment discontinuation. This not only hampers the success of treatment but also reduces the overall demand for certain medications. Furthermore, the development of drug-resistant strains of the Hepatitis B virus presents another major challenge, as it reduces the efficacy of current antiviral therapies and necessitates the constant development of new drugs. As resistance to existing treatments increases, it creates barriers for healthcare providers in managing the infection effectively, limiting the market's growth potential. These challenges contribute to hesitancy in prescribing long-term antiviral therapies, slowing the adoption of certain medications and thereby restraining market expansion

Opportunity

  •  Rising New Drug Releases and Increasing New Drug Permits for Hepatitis B

The hepatitis B market is experiencing significant growth, driven by several key factors including the rising number of new drug releases and an increase in new drug permits. The surge in drug approvals is partly a response to the persistent need for more effective antiviral therapies and vaccines to manage and potentially eradicate hepatitis B. This trend is evident from the increased investments in research and development by major pharmaceutical companies, which are focusing on innovative treatment options that offer improved efficacy, fewer side effects, and enhanced patient compliance. Additionally, advancements in drug delivery systems and the development of combination therapies have contributed to the expansion of the market. The growth in market share for hepatitis B drugs is also supported by the increasing North America prevalence of the disease, particularly in regions with high infection rates such as Asia-Pacific and sub-Saharan Africa. As new therapies become available and the market becomes more competitive, financial growth is expected to be robust, with projections indicating a substantial increase in market value over the coming years. This growth is underpinned by rising healthcare expenditure, broader healthcare access, and heightened awareness about the importance of hepatitis B management. The market is likely to see continued expansion as new players enter the field, existing companies innovate, and healthcare systems around the world prioritize hepatitis B treatment.

Challenge

  •  The Cost of hepatitis B Treatments is High
  • The high cost of hepatitis B treatments presents significant challenges for the market. One of the primary factors contributing to this challenge is the complexity of developing antiviral drugs and immunomodulators that effectively manage the virus without causing severe side effects. This complexity requires extensive research, clinical trials, and regulatory approvals, all of which drive up the price of the final product. Additionally, the ongoing nature of treatment for chronic hepatitis B means that patients often face long-term costs, which can be prohibitively expensive, particularly in regions with limited access to healthcare subsidies or insurance coverage.
  • Another challenge is the limited availability of generic versions of hepatitis B drugs. Many of the more effective treatments remain under patent protection, allowing pharmaceutical companies to maintain high prices. This lack of competition further exacerbates the financial burden on patients, healthcare systems, and governments. Moreover, the development of newer treatments, such as those aimed at complete viral eradication, is still in the early stages, with no immediate prospects for significantly lowering treatment costs in the near future.

Recent Developments

  • In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
  • In July 2024, Gilead Sciences, Inc. presented research data, showcasing long-term efficacy and safety of Biktarvy in diverse HIV populations, including Hispanic/Latine individuals and older adults with comorbidities. Investigational once-daily and weekly dosing regimens were also highlighted
  • In February 2024, GSK completed its acquisition of Aiolos Bio, including the promising AIO-001 monoclonal antibody for severe asthma. GSK paid USD 1000 million upfront and up to USD 400 million in milestone payments, expanding its respiratory biologics portfolio

North America Hepatitis B Infection Market Scope

  North America hepatitis B infection market is categorized into two notable segments which are based on the type and treatment. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

  • Chronic
  • Acute

On the basis of type, market is segmented into chronic and acute.

 Treatment

  • Vaccine
  •  Antiviral Drugs
  • Immune Modulator Drugs
  • Surgery

On the basis of treatment, market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery.

North America Hepatitis B Infection Market Regional Analysis/Insights

North America Hepatitis B Infection market is categorized  into two notable segments which are based on the type and treatment. 

The country covered in this market report are  U.S., Canada, and Mexico.

U.S. is expected to dominate the market due to development of combination therapies for hepatitis B.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and, North America Hepatitis B Infection Market Dynamics Share Analysis

يقدم المشهد التنافسي لسوق عدوى التهاب الكبد الوبائي ب في أمريكا الشمالية تفاصيل عن المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى شريان الحياة لنوع المنتج. تتعلق نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على السوق.

بعض اللاعبين الرئيسيين في السوق هم Gilead Sciences، Inc. (الولايات المتحدة)، GlaxoSmithKline plc (المملكة المتحدة)، Dynavax Technologies (الولايات المتحدة)، F. Hoffmann-La Roche Ltd (سويسرا)، Bristol-Myers Squibb Company (الولايات المتحدة)، Merck Sharp and Dohme Corp. (الولايات المتحدة)، Novartis AG (سويسرا)، Arrowhead Pharmaceuticals Inc. (الولايات المتحدة)، Arbutus Biopharma (كندا)، Teva Pharmaceuticals، Inc. (إسرائيل)، Zydus Pharmaceuticals (الهند)، Aurobindo Pharma (الهند)، Lupin Pharmaceuticals، Inc. (الهند).


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA HEPATITIS B INFECTION MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 THERAPEUTICS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTAL ANALYSIS

4.2 PORTER FIVE FORCES

5 NORTH AMERICA HEPATITIS B INFECTION MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION

5.2 NORTH AMERICA REGULATORY SCENARIO

5.3 EUROPE REGULATORY SCENARIO

5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO

5.5 SOUTH AMERICA REGULATORY SCENARIO

6 PIPELINE ANALYSIS

7 EPIDEMILIOGY

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS

8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS

8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B

8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION

8.2 RESTRAINTS

8.2.1 SIDE EFFECTS AND DRUG RESISTANCE

8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION

8.3 OPPORTUNITY

8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B

8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION

8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS

8.4 CHALLENGES

8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH

8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS

9 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE

9.1 OVERVIEW

9.2 CHRONIC

9.3 ACUTE

10 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 VACCINE

10.2.1 HOSPITAL PHARMACIES

10.2.2 DRUGS STORES AND RETAIL PHARMACIES

10.2.3 ONLINE PHARMACIES

10.3 ANTIVIRAL DRUGS

10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)

10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)

10.3.3 ENTECAVIR

10.3.4 OTHERS

10.4 IMMUNE MODULATOR DRUGS

10.4.1 PEGYLATED INTERFERON

10.4.2 INTERFERON ALPHA

10.5 SURGERY

11 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY REGION

11.1 NORTH AMERICA

11.1.1 U.S

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GILEAD SCIENCES, INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 GLAXOSMITHKLINE PLC

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 DYNAVAX TECHNOLOGIES CORPORATION

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 F. HOFFMAN-LA ROCHE LTD.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 BRISTOL-MYERS SQUIBB COMPANY

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ARROWHEAD PHARMACEUTICALS, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ARBUTUS BIOPHARMA

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT UPDATES

14.8 AUROBINDO PHARMA

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT UPDATES

14.9 LUPIN PHARMACEUTICALS, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT UPDATES

14.1 MERCK & CO., INC.,

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 NOVARTIS AG

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 TEVA PHARMACEUTICAL INDUSTRIES

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 ZYDUS PHARMACEUTICALS, INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 REVENUE

14.13.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY

TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE

TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B

TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES

TABLE 5 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 6 NORTH AMERICA CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 NORTH AMERICA ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 9 NORTH AMERICA VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 NORTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 11 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 13 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 15 NORTH AMERICA SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 17 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 18 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 19 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 20 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 21 NORTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 22 U.S. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 23 U.S. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 24 U.S. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 25 U.S. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 26 U.S. VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 27 CANADA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 28 CANADA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 29 CANADA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 30 CANADA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 31 CANADA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 32 MEXICO HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 33 MEXICO HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 34 MEXICO ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 35 MEXICO IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 36 MEXICO VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA HEPATITIS B INFECTION MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA HEPATITIS B INFECTION MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA HEPATITIS B INFECTION MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA HEPATITIS B INFECTION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA HEPATITIS B INFECTION MARKET: SEGMENTATION

FIGURE 11 TWO SEGMENTS COMPRISE THE NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE

FIGURE 12 EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 NORTH AMERICA HEPATITIS B INFECTION MARKET

FIGURE 15 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HEPATITIS B INFECTION MARKET IN 2024 & 2031

FIGURE 16 DROC ANALYSIS

FIGURE 17 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019

FIGURE 18 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TYPE, 2023

FIGURE 19 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 20 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 21 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023

FIGURE 23 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)

FIGURE 24 NORTH AMERICA HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)

FIGURE 25 NORTH AMERICA HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE

FIGURE 26 NORTH AMERICA HEPATITIS B INFECTION MARKET, SNAPSHOT

FIGURE 27 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The market is segmented based on , By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery- Industry Trends and Forecast to 2031      .
The North America Hepatitis B Infection Market size was valued at USD 2.35 USD Billion in 2023.
The North America Hepatitis B Infection Market is projected to grow at a CAGR of 4.9% during the forecast period of 2024 to 2031.
The market report covers data from the  U.S., Canada, and Mexico.